AbbVie to Acquire Apogee Therapeutics for $10.9 Billion in All-Cash Deal

summarizeSummary

Apogee Therapeutics has entered into a definitive agreement to be acquired by AbbVie Inc. for $135.11 per share in cash, valuing the company at approximately $10.9 billion. This transaction will result in Apogee becoming a wholly-owned subsidiary of AbbVie.

check_boxKey Events

• Definitive Acquisition Agreement

  Apogee Therapeutics has entered into a definitive Agreement and Plan of Merger to be acquired by AbbVie Inc. This follows the 8-K filing earlier today announcing the agreement.

• All-Cash Consideration

  AbbVie will acquire all outstanding shares of Apogee for $135.11 per share in cash, totaling approximately $10.9 billion in equity value. This represents a premium over the current stock price of $133.21 and the 52-week high of $95.315.

• Shareholder and Regulatory Approvals

  The transaction is subject to customary closing conditions, including approval by Apogee shareholders and receipt of regulatory approvals. Key stockholders, Fairmount Funds Management LLC and Venrock Associates, have already entered into voting agreements in support of the transaction.

• Expected Closing Timeline

  The acquisition is expected to close in the third quarter of 2026.

auto_awesomeAnalysis

This filing details the definitive agreement for AbbVie to acquire Apogee Therapeutics for approximately $10.9 billion in cash. This is a thesis-altering event for Apogee shareholders, as the company will cease to exist as an independent publicly traded entity. The acquisition price of $135.11 per share represents a premium over the current trading price and a significant premium over the 52-week high, offering a clear exit for investors. The transaction is subject to shareholder and regulatory approvals, with key stockholders already committed to voting in favor, indicating a high likelihood of completion.